Floating Point

Floating Point is a New York-based early-stage firm writing $1M to $5M checks at pre-seed, seed, and Series A. The fund treats AI and software as a single investable surface and has folded healthcare into that lens, looking specifically for clinical, biological, and care-delivery problems where machine learning is doing real work rather than serving as a marketing veneer. The firm is small, founder-friendly, and explicit that it is investing in technical teams rather than in pitch theater.

The thesis covers digital health, biotech, and AI and machine learning in healthcare. Within that perimeter, Floating Point is most interested in companies that combine high-quality data assets with technical talent that can extract clinical or commercial value from those assets. That includes clinical decision support, diagnostic interpretation, drug discovery infrastructure, and back-office tooling for providers and life-sciences companies. The firm avoids businesses that depend on regulatory arbitrage or on selling thin AI wrappers around commodity models, and it is comfortable saying so early in a conversation.

Check sizes of $1M to $5M let Floating Point lead small seed rounds or write meaningful follow-on checks at Series A, depending on the syndicate. The geographic focus is the United States, with occasional exposure to companies headquartered abroad but commercializing into US healthcare. Founders should expect questions about data provenance, model evaluation, and the regulatory pathway from day one, and the firm will not invest in businesses that hand-wave through any of those areas. Pre-revenue companies are welcome if the team and the technical wedge are credible.

The team is intentionally small, with partners who have technical and operating backgrounds and who do their own diligence. There are no associates running first-round screens, which means founders are talking directly to decision-makers throughout the process. That structure also limits the number of new investments per year and forces the firm to be selective about where it commits capital and time.

Floating Point engages closely with portfolio companies in the months after investment, helping with technical hiring, customer introductions, and follow-on fundraising into US growth funds. The firm does not take large board control positions and prefers to operate as a high-conviction early backer that hands the keys to operating partners as the company scales. Founders who want a small, technically literate firm that will engage on actual product and architecture questions, and who are building healthcare AI with defensible technical foundations, will find Floating Point a clean fit. Those looking for a brand-name signal investor or a passive check should keep moving.